Senolytic Therapy to Modulate Progression of Alzheimer’s Disease (SToMP-AD)

Purpose of this Study

The underlying processes driving chronic neurodegeneration in Alzheimer’s disease (AD) and related neurodegenerative disorders are largely unknown. Moreover, individuals with AD suffer from more age-associated health conditions than other older adults without AD. This research will use a combination of oral medications (dasatinib and quercetin) in an intermittent administration regimen for 12 weeks to identify whether the treatment will reach the spinal fluid or cross the blood-brain barrier, and whether it can affect the cellular life cycle and cellular inflammation that goes with aging.

You may qualify if:

  • Age 65 and older
  • A non-smoker
  • Diagnosed with Alzheimer’s disease
  • Must be accompanied by an authorized representative or family member

You may NOT qualify if:

  • Have plans to travel over the study course of 4-5 months
  • Have no currently active illness or other unstable chronic condition

Duration of the Study:

This is a 16 to 20 week study with up to 10 study visits.

Study Procedures:

  • Medical history
  • Physical examination/assessment
  • Lab work
  • MRI Testing

Study Location:

Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases
7703 Floyd Curl Drive
San Antonio, TX 78229

Compensation:

Up to $625 is offered for the completion of this study, depending on completed visits and procedures.

Principal Investigator:

Mitzi Gonzales, PhD

Nicolas Musi, MD

Contact Us

For more information or to volunteer in a study:

  • Call (210) 567-8229
  • If you prefer that we contact you, please fill out the form below.
Contact Us Clinical
reCAPTCHA